Ocular Tracer Platform
Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's)
Phase 1Active
Key Facts
Indication
Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's)
Phase
Phase 1
Status
Active
Company
About Amydis Diagnostics
Amydis Diagnostics is developing a first-in-class, non-invasive diagnostic platform that uses proprietary ocular tracers to detect molecular biomarkers in the eye via routine eye exams. This technology targets major unmet needs in neurodegenerative (e.g., Alzheimer's, Parkinson's, ALS), ophthalmic, and cardiovascular diseases by enabling earlier and more accessible diagnosis. The company is advancing its pipeline through human clinical trials with support from significant NIH grants and foundation awards, positioning itself to leverage the existing, widespread infrastructure of eye care providers as a new front line for systemic disease detection.
View full company profileTherapeutic Areas
Other Neurodegenerative Diseases (e.g., Alzheimer's, Parkinson's) Drugs
| Drug | Company | Phase |
|---|---|---|
| TCAP Platform | Protagenic Therapeutics | Preclinical |
| NeurOdys Therapeutics (Portfolio Company) | Expert Systems | Pre-clinical |
| Neurodegenerative Disease Diagnostic Program | ESP Diagnostics | Pre-clinical/Assay Development |